Equities research analysts expect CareDx Inc (NASDAQ:CDNA) to report sales of $35.87 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for CareDx’s earnings. The highest sales estimate is $36.00 million and the lowest is $35.70 million. CareDx posted sales of $23.51 million in the same quarter last year, which suggests a positive year over year growth rate of 52.6%. The firm is expected to issue its next earnings report after the market closes on Thursday, February 27th.
According to Zacks, analysts expect that CareDx will report full-year sales of $127.13 million for the current year, with estimates ranging from $127.00 million to $127.24 million. For the next financial year, analysts expect that the business will report sales of $171.31 million, with estimates ranging from $165.21 million to $180.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover CareDx.
A number of research firms have issued reports on CDNA. Piper Sandler reissued a “buy” rating and set a $63.00 target price on shares of CareDx in a research note on Monday, January 27th. Piper Jaffray Companies set a $63.00 target price on shares of CareDx and gave the company a “buy” rating in a research note on Friday, November 1st. BidaskClub raised shares of CareDx from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. ValuEngine lowered shares of CareDx from a “buy” rating to a “hold” rating in a research note on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and set a $43.00 target price on shares of CareDx in a research note on Tuesday, January 21st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $48.50.
In other news, CEO Peter Maag sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $23.13, for a total value of $231,300.00. Following the completion of the sale, the chief executive officer now directly owns 429,814 shares of the company’s stock, valued at approximately $9,941,597.82. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William A. Hagstrom sold 12,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.21, for a total transaction of $265,125.00. Over the last ninety days, insiders sold 42,016 shares of company stock valued at $1,001,547. Company insiders own 3.20% of the company’s stock.
Several large investors have recently modified their holdings of the company. Meeder Asset Management Inc. lifted its stake in shares of CareDx by 11.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,277 shares of the company’s stock worth $98,000 after acquiring an additional 433 shares during the period. Rhumbline Advisers lifted its stake in shares of CareDx by 1.1% in the 3rd quarter. Rhumbline Advisers now owns 54,776 shares of the company’s stock worth $1,238,000 after acquiring an additional 584 shares during the period. Victory Capital Management Inc. lifted its stake in shares of CareDx by 9.3% in the 4th quarter. Victory Capital Management Inc. now owns 11,308 shares of the company’s stock worth $273,000 after acquiring an additional 964 shares during the period. California State Teachers Retirement System lifted its stake in shares of CareDx by 1.6% in the 3rd quarter. California State Teachers Retirement System now owns 64,313 shares of the company’s stock worth $1,454,000 after acquiring an additional 997 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of CareDx by 21.8% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 7,530 shares of the company’s stock worth $170,000 after purchasing an additional 1,347 shares in the last quarter. 97.92% of the stock is owned by institutional investors.
CareDx stock traded up $0.05 during midday trading on Tuesday, reaching $28.25. 631,223 shares of the stock traded hands, compared to its average volume of 674,252. The firm has a fifty day moving average price of $23.54 and a two-hundred day moving average price of $23.28. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -56.50 and a beta of 0.80. CareDx has a fifty-two week low of $18.75 and a fifty-two week high of $41.27.
CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Featured Article: Average Daily Trade Volume – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.